NovaMed Pharmaceuticals(Pvt.)Ltd
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer and marketer with local, toll-manufacturing and export operations across multiple dosage forms.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- NovaMed Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 28-KM Ferozpur Road, Lahore, Pakistan
- Website
- novamed.com.pk ↗
- Phone
- +92 42 35403360-4
- info@novamed.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Enta-B | Entecavir | 0.5 mg | Tablet | 30's | 059690 | PKR 20,765.06 | PKR 692.17/tablet | 94% above median |
| Fer-P | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60ml | 043636 | PKR 144.54 | PKR 2.41/mL | Near median |
| Fer-P | Iron polymaltose complex | 50 mg/5 mL | Syrup | 120ml | 043636 | PKR 247.79 | PKR 2.06/mL | 11% below median |
| Fer-P Plus | Elemental Iron | 100 mg | Tablet | 2x10's | 049424 | PKR 264.66 | PKR 13.23/tablet | Near median |
| Fer-P Plus | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 3x10's | 049424 | PKR 392.91 | PKR 13.10/tablet | Near median |
| Fer-P Plus | Elemental Iron | 100 mg | Tablet | 1x10's | 049424 | PKR 142.50 | PKR 14.25/tablet | Near median |
| Fitem | Ceftazidime | 250 mg | Injection | 1's | 045039 | PKR 167.85 | PKR 167.85/vial/unit | Near median |
| Fitem | Ceftazidime | 500 mg | Injection | 1's | 045040 | PKR 255.31 | PKR 255.31/vial/unit | Near median |
| Fitem | Ceftazidime | 1 g | Injection | 1's | 045041 | PKR 479.57 | PKR 479.57/vial/unit | Near median |
| Fosbir | Sofosbuvir | 90 mg | Tablet | 28's | 095842 | PKR 49,634.86 | PKR 1,772.67/tablet | 15% below median |
| Gempaz | Empagliflozin | 10 mg | Tablet | 14's | 116560 | PKR 858.16 | PKR 61.30/tablet | 26% below median |
| Gempaz | Empagliflozin | 25 mg | Tablet | 14's | 116561 | PKR 1,027.16 | PKR 73.37/tablet | 27% below median |
| Genops | Gentamicin | 0.3 % | Ophthalmic drops | 7.5ml | 084886 | PKR 46.32 | PKR 6.18/mL | 33% above median |
| Glazid MR | Gliclazide | 60 mg | Tablet | 3x10's | 065748 | PKR 764.01 | PKR 25.47/tablet | 6% above median |
| Glazid MR | Gliclazide | 60 mg | Tablet | 1x10's | 065748 | PKR 276.70 | PKR 27.67/tablet | 15% above median |
| Glazid MR | Gliclazide | 60 mg | Tablet | 20's | 065748 | PKR 553.39 | PKR 27.67/tablet | 15% above median |
| Glazid MR | Gliclazide | 30 mg | Tablet | 3x10's | 065749 | PKR 402.66 | PKR 13.42/tablet | Near median |
| Glazid MR | Gliclazide | 30 mg | Tablet | 20's | 065749 | PKR 268.44 | PKR 13.42/tablet | Near median |
| Glimin | Gliclazide | 80 mg | Tablet | 3x10's | 069159 | PKR 368.96 | PKR 12.30/tablet | 18% above median |
| Glimin | Gliclazide | 80 mg | Tablet | 20's | 069159 | PKR 245.27 | PKR 12.26/tablet | 17% above median |
| Glimin Forte | Gliclazide | 160 mg | Tablet | 3x10's | 069160 | PKR 550.24 | PKR 18.34/tablet | Near median |
| Glimin Forte | Gliclazide | 160 mg | Tablet | 20's | 069160 | PKR 366.83 | PKR 18.34/tablet | Near median |
| Ibofen | Ibuprofen | 100 mg/5 mL | Suspension | 1x90ml | 043626 | PKR 101.62 | PKR 1.13/mL | 19% above median |
| Ibofen | Ibuprofen | 100 mg/5 mL | Suspension | 1x120ml | 043626 | PKR 135.50 | PKR 1.13/mL | 19% above median |
| Ibofen | Ibuprofen | 100 mg/5 mL | Suspension | 1x450ml | 043626 | PKR 487.80 | PKR 1.08/mL | 15% above median |
| Ibofen | Ibuprofen | 100 mg/5 mL | Suspension | 1x60ml | 043626 | PKR 67.75 | PKR 1.13/mL | 19% above median |
| Ibofen | Ibuprofen | 400 mg/100 mL | IV infusion | 100ml | 136630 | PKR 369.00 | PKR 3.69/mL | 16% below median |
| Icef | Cefixime | 200 mg | Capsule | 1x5's | 049420 | PKR 351.89 | PKR 70.38/capsule | 12% above median |
| Iohex 350 | Iohexol | 755 mg/mL (equiv. iodine 350 mg/mL) | Injection | 50ml | 121435 | PKR 3,763.88 | PKR 75.28/mL | 33% above median |
| Iohex 350 | Iohexol | 350 mg iodine/mL | Injection | 100ml | 121436 | PKR 5,644.66 | PKR 56.45/mL | No comparator |
| Ironone | Iron polymaltose complex | 150 mg | Capsule | 30's | 097533 | PKR 706.52 | PKR 23.55/capsule | 6% above median |
| Ironone | Polysaccharide iron complex | 150 mg | Capsule | 15's | 097533 | PKR 360.46 | PKR 24.03/capsule | 8% above median |
| Ironone | Polysaccharide iron complex | 217.4 mg/5 mL | Syrup | 120ml | 097534 | PKR 264.98 | PKR 2.21/mL | No comparator |
| Lamidin | Lamivudine | 100 mg | Tablet | 1x10's | 054152 | PKR 578.17 | PKR 57.82/tablet | Near median |
| Letam | Levetiracetam | 500 mg/5 mL | Injection | 10's(5ml) Vial | 119000 | PKR 3,273.99 | — | No comparator |
| Lignox | Lidocaine | 20 mg/mL | Injection | 50's(2ml) | 076968 | PKR 174.71 | — | No comparator |
| Limet | Linezolid | 200 mg | IV infusion | 1x100ml | 078717 | PKR 725.24 | PKR 7.25/mL | 6% above median |
| Linzod | Linezolid | 400 mg | Tablet | 12's | 082663 | PKR 2,911.69 | PKR 242.64/tablet | 5% above median |
| Linzod | Linezolid | 600 mg/300 mL | IV infusion | 1x300ml | 089402 | PKR 1,196.58 | PKR 3.99/mL | Near median |
| Linzod | Linezolid | 600 mg | Tablet | 12's | 089403 | PKR 5,097.45 | PKR 424.79/tablet | 8% above median |
| Linzod | Linezolid | 200 mg/100 mL | IV infusion | 1x100ml | 089404 | PKR 690.03 | PKR 6.90/mL | Near median |
| Lyvial 200 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 106002 | PKR 11,525.21 | PKR 96.04/tablet | Near median |
| Maxlox | Moxifloxacin | 400 mg | Tablet | 1x5's | 043490 | PKR 897.44 | PKR 179.49/tablet | Near median |
| Merenium | Meropenem | 1 g | IV injection | 1's | 117587 | PKR 2,316.23 | PKR 2,316.23/vial/unit | 40% below median |
| Merenium | Meropenem | 500 mg | IV injection | 1's | 117588 | PKR 1,239.18 | PKR 1,239.18/vial/unit | 40% below median |
| Murocen | Mupirocin | 2% | Ointment | 15gm | 084885 | PKR 217.73 | PKR 14.52/g | Near median |
| Nov-C | Ascorbic acid | 500 mg | Chewable tablet | 40's | 106003 | PKR 53.06 | PKR 1.33/tablet | Near median |
| Novaterafine | Terbinafine | 1 % | Cream | 10gm | 089407 | PKR 294.42 | PKR 29.44/g | Near median |
| Novaxone | Ceftriaxone | 2 g | IV injection | 1's | 102463 | PKR 722.58 | PKR 722.58/vial/unit | 15% below median |
| Nufex Paediatric (Granules for | Cephalexin | 100 mg | Oral drops | 10ml | 082662 | PKR 105.14 | PKR 10.51/mL | 14% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.